

Robert C Bast

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9394048/robert-c-bast-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

434
papers

45,363
citations

95
h-index

203
g-index

521
ext. papers

49,966
ext. citations

6.4
avg, IF

6.77
L-index

#	Paper	IF	Citations
434	DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy. <i>Molecular Cancer Therapeutics</i> , 2021 ,	6.1	1
433	Next steps in the early detection of ovarian cancer. <i>Communications Medicine</i> , 2021 , 1,		1
432	A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. <i>Cancers</i> , 2021 , 13,	6.6	2
431	Directed evolution of cyclic peptides for inhibition of autophagy. <i>Chemical Science</i> , 2021 , 12, 3526-3543	9.4	8
430	A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
429	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. <i>Oncogenesis</i> , 2021 , 10, 65	6.6	3
428	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). <i>Autophagy</i> , 2021 , 17, 1-382	10.2	440
427	Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.. <i>Tumor Biology</i> , 2021 , 43, 355-365	2.9	1
426	Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 12121-12130	11.5	8
425	Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. <i>Cancer</i> , 2020 , 126, 3579-3592	6.4	7
424	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. <i>PLoS Genetics</i> , 2020 , 16, e1008808	6	15
423	Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. <i>Cancers</i> , 2020 , 12,	6.6	7
422	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. <i>Cancer</i> , 2020 , 126, 894-907	6.4	27
421	SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. <i>International Journal of Cancer</i> , 2020 , 146, 1553-1567	7.5	21
420	Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. <i>Cancer</i> , 2020 , 126, 725-736	6.4	14
419	Biomarkers and Strategies for Early Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2504-2512	4	22
418	Targeting progesterone signaling prevents metastatic ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 31993-32004	11.5	9

417	The National Cancer Institute Early Detection Research Network: Two Decades of Progress. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2396-2400	4	2
416	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. <i>Cancers</i> , 2020 , 12,	6.6	7
415	Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" 2019, , 596: Markers for Early Detection of Ovarian Cancer. <i>Cancers</i> , 2019 , 11,	6.6	1
414	Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. <i>Cancer Prevention Research</i> , 2019 , 12, 171-184	3.2	5
413	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1956-1964	2.2	113
412	Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. <i>Cancers</i> , 2019 , 11,	6.6	13
411	DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. <i>Cancers</i> , 2019 , 11,	6.6	10
410	Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. <i>Cancers</i> , 2019 , 11,	6.6	11
409	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019 , 125, 1963-1972	6.4	22
408	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019 , 12, 391-400	3.2	12
407	Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 705-708	3.6	8
406	Novel Approaches to Ovarian Cancer Screening. <i>Current Oncology Reports</i> , 2019 , 21, 75	6.3	19
405	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. <i>Clinical Cancer Research</i> , 2019 , 25, 5702-5716	12.9	14
404	DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. <i>Cell Reports</i> , 2019 , 29, 3448-3459.e6	10.6	22
403	The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. <i>Cancer</i> , 2019 , 125, 1267-1280	6.4	16
402	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. <i>Nature Communications</i> , 2018 , 9, 476	17.4	31
401	RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. <i>Autophagy</i> , 2018 , 14, 637-653	10.2	29
400	Potentially inappropriate medication use in older patients with breast and colorectal cancer. <i>Cancer</i> , 2018 , 124, 3000-3007	6.4	28

399	Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. <i>Clinical Cancer Research</i> , 2018 , 24, 5072-5084	12.9	19
398	Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13019-e13019	2.2	1
397	Cell Origins of High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018 , 10,	6.6	87
396	Early Detection of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018 , 32, 903-914	3.1	53
395	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR- β <i>Investigational New Drugs</i> , 2018 , 36, 1103-1109	4.3	9
394	Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. <i>Bioconjugate Chemistry</i> , 2018 , 29, 3180-3195	6.3	15
393	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer 2017 , 1-27		0
392	Molecular Diagnostics in Cancer 2017 , 1-14		2
391	Monoclonal Serotherapy 2017 , 1-23		3
390	The role of biomarkers in the management of epithelial ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 577-591	3.8	74
389	Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. <i>Autophagy</i> , 2017 , 13, 506-521	10.2	63
388	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2838-2847	2.2	178
387	In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. <i>ACS Applied Materials & Interfaces</i> , 2017 , 9, 41680-41690	9.5	15
386	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5912-5922	12.9	31
385	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. <i>Clinical Cancer Research</i> , 2017 , 23, 1945-1954	12.9	27
384	Abstract 1864: Feasibility of magnetic relaxometry for early ovarian cancer detection: preliminary evaluation of sensitivity and specificity in cell culture and in mice 2017 ,		2
383	Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. <i>Oncotarget</i> , 2017 , 8, 17960-17980	3.5	0
382	Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1 α /cyclin D1 pathway. <i>Oncogene</i> , 2016 , 35, 2506-17	9.2	67

381	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. <i>Cancer Cell</i> , 2016 , 30, 273-289	24.3	92
380	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1333-40	4	31
379	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. <i>EBioMedicine</i> , 2016 , 10, 137-49	8.8	29
378	Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. <i>BMC Cancer</i> , 2016 , 16, 824	4.8	17
377	Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition. <i>EBioMedicine</i> , 2016 , 6, 149-161	8.8	31
376	Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. <i>Medical Oncology</i> , 2016 , 33, 73	3.7	15
375	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
374	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1134-50	2.2	543
373	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. <i>Molecular Cell</i> , 2016 , 61, 520-534	17.6	101
372	Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. <i>Laboratory Investigation</i> , 2016 , 96, 37-48	5.9	27
371	Validation of a multi-marker panel for early detection of ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5570-5570	2.2	1
370	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. <i>Genes and Cancer</i> , 2016 , 7, 60-72	2.9	28
369	NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. <i>Oncotarget</i> , 2016 , 7, 3018-32	3.3	9
368	Tumor necrosis factor- α and interferon- β stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFB. <i>Oncotarget</i> , 2016 , 7, 14871-84	3.3	34
367	Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 1070-7	3.5	25
366	Linking genomic reorganization to tumor initiation via the giant cell cycle. <i>Oncogenesis</i> , 2016 , 5, e281	6.6	81
365	Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 43-51	3.5	143
364	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2695-704	2.2	214

363	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
362	A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. <i>Cancer Prevention Research</i> , 2015 , 8, 37-48	3.2	44
361	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79	31.3	581
360	Molecular Pathogenesis of Ovarian Cancer 2015 , 531-548.e2		2
359	ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. <i>Cell Death and Disease</i> , 2015 , 6, e1836	9.8	37
358	How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. <i>Cancer</i> , 2015 , 121, 806-16	6.4	9
357	Clinically relevant microRNAs in ovarian cancer. <i>Molecular Cancer Research</i> , 2015 , 13, 393-401	6.6	75
356	Cancer Stem Cell Principles 2015 , 39-46		1
355	Abstract 2838: TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer 2015 ,		2
354	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. <i>PLoS ONE</i> , 2015 , 10, e0131833	3.7	18
353	DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. <i>Autophagy</i> , 2014 , 10, 1071-92	10.2	46
352	ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. <i>Cell Death and Differentiation</i> , 2014 , 21, 1275-89	12.7	53
351	Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. <i>Clinical Cancer Research</i> , 2014 , 20, 5708-19	12.9	82
350	Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 210, 257.e1-6	6.4	7
349	Recurrent Ovarian Cancer: When to Treat and How to Assess 2014 , 17-27		
348	The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy 2014 , 99-109		
347	Low-grade serous carcinoma: new concepts and emerging therapies. <i>Gynecologic Oncology</i> , 2013 , 130, 660-6	4.9	49
346	A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. <i>Cancer</i> , 2013 , 119, 3454-61	6.4	90

345	Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. <i>Epigenetics</i> , 2013 , 8, 1330-46	5.7	45
344	Conquering cancer in our lifetime: new diagnostic and therapeutic trends. <i>Clinical Chemistry</i> , 2013 , 59, 1-3	5.5	19
343	Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. <i>Clinical Chemistry</i> , 2013 , 59, 22-31	5.5	28
342	FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. <i>Endocrine-Related Cancer</i> , 2013 , 20, 415-29	5.7	26
341	The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. <i>Cell Adhesion and Migration</i> , 2013 , 7, 232-6	3.2	20
340	Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. <i>International Journal of Oncology</i> , 2013 , 43, 1194-204	4.4	33
339	CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 815-22	3.5	30
338	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. <i>Frontiers in Oncology</i> , 2013 , 3, 58	5.3	17
337	The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. <i>Oncology</i> , 2013 , 27, 548-56	1.8	42
336	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 126, 47-53	4.9	62
335	Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. <i>Cancer</i> , 2012 , 118, 91-100	6.4	68
334	Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. <i>BMC Cancer</i> , 2012 , 12, 243	4.8	43
333	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-544.2	4.2	2783
332	Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. <i>Cancer Letters</i> , 2012 , 326, 176-82	9.9	29
331	Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. <i>PLoS ONE</i> , 2012 , 7, e41170	3.7	54
330	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. <i>Cancer</i> , 2012 , 118, 2603-14	6.4	220
329	The origin of ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012 , 119, 134-6	3.7	14
328	Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 206, 349.e1-7	6.4	102

327	Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 206, 351.e1-8	6.4	93
326	Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. <i>Endocrinology</i> , 2012 , 153, 1593-602	4.8	213
325	Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1034-41	4.6	12
324	The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. <i>Oncogene</i> , 2012 , 31, 68-79	9.2	70
323	Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. <i>Oncogene</i> , 2012 , 31, 2450-60	9.0	30
322	Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. <i>Cancer Discovery</i> , 2012 , 2, 16-8	24.4	27
321	Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. <i>Cancer Prevention Research</i> , 2012 , 5, 706-16	3.2	31
320	Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. <i>International Journal of Gynecological Cancer</i> , 2012 , 22 Suppl 1, S5-8	3.5	50
319	A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. <i>Journal of Experimental Therapeutics and Oncology</i> , 2012 , 10, 155-62	0.8	29
318	Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 3549-63	8.3	104
317	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25	31.3	893
316	More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. <i>Gynecologic Oncology</i> , 2011 , 121, 429-30	4.9	39
315	Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011 , 122, 548-53	4.9	61
314	A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1033-44	3.5	13
313	Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. <i>BMC Cancer</i> , 2011 , 11, 22	4.8	56
312	Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. <i>Cancer</i> , 2011 , 117, 1661-9	6.4	128
311	Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. <i>Cancer</i> , 2011 , 117, 4424-38	6.4	105
310	The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1403-22	9.7	26

309	A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 375-83	3.2	130
308	Reproducibility of SELDI Spectra Across Time and Laboratories. <i>Cancer Informatics</i> , 2011 , 10, 45-64	2.4	14
307	FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. <i>Cancer Research</i> , 2011 , 71, 6878-87	10.1	37
306	Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. <i>Cancer Prevention Research</i> , 2011 , 4, 365-74	3.2	221
305	Src family kinases and paclitaxel sensitivity. <i>Cancer Biology and Therapy</i> , 2011 , 12, 260-9	4.6	66
304	Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. <i>Cancer Research</i> , 2011 , 71, 5806-17	10.1	43
303	A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies. <i>Biometrics</i> , 2010 , 66, 1275-83	1.8	15
302	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 3186-99	6.1	284
301	Personalizing therapy for ovarian cancer: BRCAness and beyond. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3545-8	2.2	52
300	Stanniocalcin 1 and ovarian tumorigenesis. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 812-27	9.7	90
299	Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2010 , 3, 9	22.4	20
298	Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010 , 3, 81-97		3
297	AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. <i>Clinical Cancer Research</i> , 2010 , 16, 3299-318	12.9	149
296	Development of a multimarker assay for early detection of ovarian cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2159-66	2.2	219
295	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. <i>Cell Cycle</i> , 2010 , 9, 140-6	4.7	13
294	Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. <i>Molecular Medicine Reports</i> , 2010 , 3, 581-7	2.9	9
293	p27Kip1 as a Biomarker and Target for Treatment of Cancer 2010 , 215-233		
292	The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. <i>Cancer Microenvironment</i> , 2010 , 3, 137-47	6.1	81

291	Combined use of biomarkers for detection of ovarian cancer in high-risk women. <i>Tumor Biology</i> , 2010 , 31, 209-15	2.9	30
290	Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. <i>BMC Cancer</i> , 2010 , 10, 378	4.8	43
289	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. <i>American Journal of Obstetrics and Gynecology</i> , 2010 , 203, 228.e1-6	6.4	173
288	SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. <i>Cancer Cell</i> , 2010 , 18, 109-21	24.3	101
287	Current state of biomarker development for clinical application in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 116, 240-5	4.9	71
286	Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. <i>Gynecologic Oncology</i> , 2010 , 117, 440-5	4.9	119
285	CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. <i>Cancer</i> , 2010 , 116, 2850-3	6.4	46
284	Dasatinib induces autophagic cell death in human ovarian cancer. <i>Cancer</i> , 2010 , 116, 4980-90	6.4	65
283	Ovarian Cancer Screening 2010 , 87-107		
282	ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. <i>Bioscience Reports</i> , 2009 , 30, 159-68	4.1	21
281	A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2375-82	6.1	29
280	Project Zero Delay: a process for accelerating the activation of cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4433-40	2.2	14
279	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2009 , 112, 40-6	4.9	557
278	Urinary levels of Bcl-2 are elevated in ovarian cancer patients. <i>Gynecologic Oncology</i> , 2009 , 112, 60-7	4.9	28
277	MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. <i>Cancer</i> , 2009 , 115, 3897-908	6.4	27
276	The biology of ovarian cancer: new opportunities for translation. <i>Nature Reviews Cancer</i> , 2009 , 9, 415-28 _{31,3}		1024
275	CA125/MUC16 is dispensable for mouse development and reproduction. <i>PLoS ONE</i> , 2009 , 4, e4675	3.7	30
274	Tumor suppressor genes. <i>Cancer Treatment and Research</i> , 2009 , 149, 109-29	3.5	2

273	MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. <i>Differentiation</i> , 2008 , 76, 1081-92	3.5	42
272	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2008 , 108, 402-8	4.9	506
271	Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. <i>Gynecologic Oncology</i> , 2008 , 108, 652-7	4.9	19
270	Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. <i>Gynecologic Oncology</i> , 2008 , 110, 196-201	4.9	154
269	Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. <i>Cell Cycle</i> , 2008 , 7, 3747-58	4.7	51
268	Early detection of ovarian cancer. <i>Biomarkers in Medicine</i> , 2008 , 2, 291-303	2.3	57
267	Molecular Pathogenesis of Epithelial Ovarian Cancer 2008 , 441-454		1
266	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. <i>Molecular Carcinogenesis</i> , 2008 , 47, 701-6	5	218
265	Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. <i>Cancer</i> , 2008 , 112, 1489-502	6.4	130
264	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <i>Clinical Chemistry</i> , 2008 , 54, e11-79	5.5	451
263	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3917-29	15.9	298
262	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5287-312	2.2	1760
261	Early detection of ovarian cancer. <i>Disease Markers</i> , 2007 , 23, 397-410	3.2	179
260	Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. <i>Gynecologic Oncology</i> , 2007 , 106, 490-7	4.9	52
259	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2007 , 107, 526-31	4.9	80
258	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. <i>Carcinogenesis</i> , 2007 , 28, 174-82	4.6	57
257	Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2843-57	6.1	38
256	Correlation between CpG methylation profiles and hormone receptor status in breast cancers. <i>Breast Cancer Research</i> , 2007 , 9, R57	8.3	112

255	Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. <i>Frontiers in Bioscience - Landmark</i> , 2007 , 12, 2260-8	2.8	7
254	Prevention and early detection of ovarian cancer: mission impossible?. <i>Recent Results in Cancer Research</i> , 2007 , 174, 91-100	1.5	78
253	Biomarkers and clinical trial design. <i>Gynecologic Oncology</i> , 2006 , 103, S3-5	4.9	3
252	The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. <i>Cancer</i> , 2006 , 107, 2730-40	6.4	113
251	4-HPR modulates gene expression in ovarian cells. <i>International Journal of Cancer</i> , 2006 , 119, 1005-13	7.5	6
250	Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. <i>Cell Cycle</i> , 2006 , 5, 1654-61	4.7	23
249	Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 2404-13	12.9	45
248	Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. <i>Cancer Research</i> , 2006 , 66, 2740-8	10.1	72
247	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 16472-7	11.5	256
246	Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. <i>Methods in Enzymology</i> , 2006 , 407, 660-76	1.7	15
245	Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. <i>Methods in Enzymology</i> , 2006 , 407, 455-68	1.7	48
244	Targeting Aurora kinases in ovarian cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2006 , 10, 77-85	6.4	18
243	ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5313-27	2.2	1129
242	Clinical application of oxaliplatin in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2006 , 16, 1717-32	3.5	24
241	HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. <i>Oncogene</i> , 2006 , 25, 6986-96	9.2	136
240	Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. <i>Clinical Cancer Research</i> , 2005 , 11, 6116-26	12.9	250
239	New tumor markers: CA125 and beyond. <i>International Journal of Gynecological Cancer</i> , 2005 , 15 Suppl 3, 274-81	3.5	366
238	Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. <i>Oncogene</i> , 2005 , 24, 6174-84	9.2	28

237	In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 98, 182-92	4.9	16
236	Potential markers that complement expression of CA125 in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 99, 267-77	4.9	279
235	Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7919-26	2.2	190
234	A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. <i>Cancer Research</i> , 2005 , 65, 6701-10	10.1	39
233	Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. <i>Clinical Cancer Research</i> , 2005 , 11, 2149-55	12.9	129
232	Translational crossroads for biomarkers. <i>Clinical Cancer Research</i> , 2005 , 11, 6103-8	12.9	64
231	Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. <i>Journal of Biological Chemistry</i> , 2005 , 280, 2092-104	5.4	49
230	HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. <i>Cell Cycle</i> , 2005 , 4, 87-95	4.7	113
229	Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 632-7	12.9	54
228	Individualized care for patients with cancer - a work in progress. <i>New England Journal of Medicine</i> , 2004 , 351, 2865-7	59.2	44
227	Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. <i>Journal of Biological Chemistry</i> , 2004 , 279, 9653-61	5.4	153
226	Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. <i>Clinical Cancer Research</i> , 2004 , 10, 3881-4	12.9	51
225	Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. <i>Clinical Cancer Research</i> , 2004 , 10, 6559-66	12.9	54
224	Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4059-66	2.2	140
223	Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. <i>Cancer Research</i> , 2004 , 64, 5882-90	10.1	796
222	Expression of BAG-1 and Bcl-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. <i>Cancer Investigation</i> , 2004 , 22, 248-56	2.1	28
221	Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 3919-26	12.9	106
220	Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. <i>Journal of Biological Chemistry</i> , 2004 , 279, 4339-45	5.4	90

219	Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. <i>Journal of Biological Chemistry</i> , 2004 , 279, 7576-83	5.4	67
218	A genetically defined model for human ovarian cancer. <i>Cancer Research</i> , 2004 , 64, 1655-63	10.1	233
217	Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004 , 33, 1219-24	4.4	19
216	Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. <i>Clinical Cancer Research</i> , 2004 , 10, 3291-300	12.9	358
215	Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer 2004 , 625-645		
214	Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. <i>Transactions of the American Clinical and Climatological Association</i> , 2004 , 115, 233-47; discussion 247-8	0.9	26
213	The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. <i>Journal of Biological Chemistry</i> , 2003 , 278, 23441-50	5.4	117
212	Progress in the management of gynecologic cancer: consensus summary statement. <i>Journal of Clinical Oncology</i> , 2003 , 21, 129s-132s	2.2	45
211	Specific keynote: chemoprevention of ovarian cancer: the journey begins. <i>Gynecologic Oncology</i> , 2003 , 88, S59-66; discussion S67-70	4.9	9
210	General keynote: molecular therapeutics and pharmacogenomics. <i>Gynecologic Oncology</i> , 2003 , 88, S84-7; discussion S93-6	4.9	2
209	Specific keynote: molecular therapeutics in ovarian cancer. <i>Gynecologic Oncology</i> , 2003 , 88, S88-92; discussion S93-6	4.9	21
208	Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. <i>Gynecologic Oncology</i> , 2003 , 88, 73-9	4.9	150
207	Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. <i>Seminars in Oncology</i> , 2003 , 30, 93-104	5.5	34
206	Overexpression of kallikrein 10 in epithelial ovarian carcinomas. <i>Gynecologic Oncology</i> , 2003 , 90, 44-50	4.9	59
205	Targeted therapy for epithelial ovarian cancer: current status and future prospects. <i>International Journal of Gynecological Cancer</i> , 2003 , 13, 701-34	3.5	39
204	Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. <i>Oncogene</i> , 2003 , 22, 484-97	9.2	50
203	ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. <i>Oncogene</i> , 2003 , 22, 2897-909	9.2	89
202	Epigenetic regulation of ARHI in breast and ovarian cancer cells. <i>Annals of the New York Academy of Sciences</i> , 2003 , 983, 268-77	6.5	69

201	Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. <i>Human Molecular Genetics</i> , 2003 , 12, 1791-800	5.6	62
200	Status of tumor markers in ovarian cancer screening. <i>Journal of Clinical Oncology</i> , 2003 , 21, 200s-205s	2.2	153
199	Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. <i>Cancer Research</i> , 2003 , 63, 4174-80	10.1	63
198	Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 3660-6	12.9	47
197	Heregulin-induced apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2002 , 7, 483-91	5.4	16
196	Characterization of the ARHI Tumor-Suppressor as a Target for Gene Therapy in Ovarian Cancer*. <i>Geburtshilfe Und Frauenheilkunde</i> , 2002 , 62, 870-876	2	
195	Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. <i>Journal of Biomedical Optics</i> , 2002 , 7, 20-6	3.5	21
194	Early detection of ovarian cancer: promise and reality. <i>Cancer Treatment and Research</i> , 2002 , 107, 61-97	3.5	102
193	Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. <i>Cancer Research</i> , 2002 , 62, 7264-72	10.1	54
192	2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1865-78	2.2	643
191	Fluorescence spectroscopy for in vivo characterization of ovarian tissue. <i>Lasers in Surgery and Medicine</i> , 2001 , 29, 128-35	3.6	39
190	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. <i>Cancer</i> , 2001 , 92, 2837-44	6.4	81
189	Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. <i>Gynecologic Oncology</i> , 2001 , 80, 145-55	4.9	27
188	Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. <i>Gynecologic Oncology</i> , 2001 , 80, 245-53	4.9	76
187	High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2001 , 82, 420-6	4.9	16
186	Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. <i>Oncogene</i> , 2001 , 20, 8258-69	9.2	41
185	Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2001 , 1519, 216-22		31
184	Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. <i>Cancer Investigation</i> , 2001 , 19, 459-66	2.1	7

183	Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1437-9	9.7	60
182	Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers. <i>Methods in Molecular Medicine</i> , 2001 , 39, 37-48		3
181	Translational research--traffic on the bridge. <i>Biomedicine and Pharmacotherapy</i> , 2001 , 55, 565-71	7.5	9
180	Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1716-22	2.2	54
179	Lysophosphatidic acid prevents apoptosis in fibroblasts via Gi-protein-mediated activation of mitogen-activated protein kinase. <i>Biochemical Journal</i> , 2000 , 352, 135	3.8	35
178	Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. <i>Biochemical Journal</i> , 2000 , 352, 475	3.8	12
177	ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. <i>International Journal of Cancer</i> , 2000 , 86, 690-4	7.5	44
176	Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. <i>International Journal of Cancer</i> , 2000 , 89, 519-523	7.5	21
175	Molecular approaches to management of epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000 , 10, 2-7	3.5	10
174	High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. <i>Bone Marrow Transplantation</i> , 2000 , 25, 1137-40	4.4	7
173	Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. <i>Oncogene</i> , 2000 , 19, 6277-85	9.2	8
172	Long-term follow-up of the Stockholm screening study on ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 79, 466-70	4.9	20
171	Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 11960-5	11.5	615
170	OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage. <i>Clinical Chemistry</i> , 1999 , 45, 692-694	5.5	14
169	NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 214-9	11.5	262
168	Ovarian cancer identified through screening with serum markers but not by pelvic imaging. <i>International Journal of Gynecological Cancer</i> , 1999 , 9, 497-501	3.5	13
167	Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. <i>Oncogene</i> , 1999 , 18, 6635-40	9.2	226
166	Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. <i>Gynecologic Oncology</i> , 1999 , 73, 56-61	4.9	64

165	Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. <i>Gynecologic Oncology</i> , 1999 , 75, 261-6	4.9	47
164	Communication skills training in oncology 1999 , 86, 887-897		157
163	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. <i>Cancer</i> , 1999 , 86, 1251-7	6.4	20
162	Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. <i>International Journal of Cancer</i> , 1999 , 82, 525-31	7.5	21
161	Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. <i>Nuclear Medicine and Biology</i> , 1999 , 26, 781-90	2.1	31
160	Communication skills training in oncology 1999 , 86, 887		9
159	Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 1998 , 70, 49-55	4.9	4
158	A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 70, 404-9	4.9	36
157	Expression of p16 induces transcriptional downregulation of the RB gene. <i>Oncogene</i> , 1998 , 16, 1-8	9.2	67
156	Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. <i>Acta Oncologica</i> , 1998 , 37, 629-40	3.2	16
155	1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 1998 , 16, 793-5	2.2	109
154	CA 125 in Ovarian Cancer: Advances and Controversy. <i>Clinical Chemistry</i> , 1998 , 44, 1379-1380	5.5	77
153	Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. <i>Journal of Biological Chemistry</i> , 1997 , 272, 13683-9	5.4	63
152	Is OVX1 a suitable marker for endometrial cancer?. <i>Gynecologic Oncology</i> , 1997 , 65, 291-6	4.9	21
151	Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. <i>Oncogene</i> , 1997 , 15, 2589-96	9.2	134
150	Conclusions and recommendations from the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer, May 10-14, 1997, Los Angeles, California, USA. <i>International Journal of Gynecological Cancer</i> , 1997 , 7, 416-424	3.5	2
149	Radioiodinated antibody targeting of the HER-2/neu oncoprotein. <i>Nuclear Medicine and Biology</i> , 1997 , 24, 451-9	2.1	5
148	Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. <i>Gynecologic Oncology</i> , 1996 , 61, 233-40	4.9	17

147	Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. <i>Gynecologic Oncology</i> , 1996 , 62, 89-99	4.9	74
146	Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. <i>Human Pathology</i> , 1996 , 27, 1185-91	3.7	129
145	Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2843-77	2.2	440
144	Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. <i>Breast Cancer Research and Treatment</i> , 1996 , 41, 1-13	4.4	45
143	Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1996 , 174, 1316-9	6.4	9
142	Expression of cell regulatory proteins in ovarian borderline tumors. <i>Cancer</i> , 1996 , 77, 2092-8	6.4	20
141	Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1996 , 6, 156-158	3.5	2
140	A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. <i>Stem Cells and Development</i> , 1996 , 5, 57-62		21
139	Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 15346-51	11.5	130
138	Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. <i>Gynecologic Oncology</i> , 1995 , 59, 111-6	4.9	91
137	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. <i>Cancer</i> , 1995 , 76, 1615-20	6.4	16
136	Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. <i>Cancer</i> , 1995 , 76, 2004-10	6.4	183
135	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. <i>Cancer</i> , 1995 , 76, 2092-6	6.4	74
134	Molecular approaches to prevention and detection of epithelial ovarian cancer. <i>Journal of Cellular Biochemistry</i> , 1995 , 23, 219-22	4.7	17
133	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. <i>Cancer</i> , 1995 , 76, 2092-2096	6.4	6
132	Pathogenesis of ovarian cancers. <i>Journal of the Society for Gynecologic Investigation</i> , 1994 , 1, 181-90		36
131	A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. <i>Human Molecular Genetics</i> , 1994 , 3, 589-94	5.6	92
130	OVX1 as a marker for early stage endometrial carcinoma. <i>Cancer</i> , 1994 , 73, 1855-8	6.4	9

129	Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. <i>Cancer</i> , 1994 , 73, 2380-5	6.4	136
128	Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. <i>Cancer</i> , 1994 , 74, 93-9	6.4	58
127	Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. <i>International Journal of Cancer</i> , 1994 , 56, 552-9	7.5	108
126	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. <i>International Journal of Cancer</i> , 1994 , 59, 242-7	7.5	14
125	Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. <i>Nature</i> , 1994 , 370, 558-61	50.4	541
124	Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. <i>Gynecologic Oncology</i> , 1994 , 52, 232-6	4.9	68
123	Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. <i>Gynecologic Oncology</i> , 1994 , 53, 59-63	4.9	13
122	Clinical and laboratory directions for ovarian cancer research. <i>Gynecologic Oncology</i> , 1994 , 55, S164-7	4.9	
121	Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. <i>American Journal of Obstetrics and Gynecology</i> , 1994 , 170, 1177-83	6.4	72
120	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. <i>American Journal of Obstetrics and Gynecology</i> , 1994 , 170, 1285-96	6.4	27
119	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. <i>American Journal of Obstetrics and Gynecology</i> , 1994 , 170, 246-52	6.4	132
118	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. <i>American Journal of Obstetrics and Gynecology</i> , 1994 , 170, 246-252	6.4	120
117	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. <i>American Journal of Obstetrics and Gynecology</i> , 1994 , 170, 1285-1296	6.4	28
116	Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. <i>American Journal of Clinical Pathology</i> , 1994 , 101, 192-7	1.9	55
115	Growth regulation and transformation of ovarian epithelium. <i>Cancer</i> , 1993 , 71, 545-51	6.4	45
114	Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. <i>Experimental Cell Research</i> , 1993 , 207, 332-9	4.2	60
113	The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. <i>American Journal of Obstetrics and Gynecology</i> , 1993 , 168, 228-32	6.4	28
112	Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. <i>American Journal of Obstetrics and Gynecology</i> , 1993 , 169, 690-4	6.4	52

111	Progress in radioimmunotherapy. <i>New England Journal of Medicine</i> , 1993 , 329, 1266-8	59.2	7
110	The biology of ovarian cancer. <i>Current Opinion in Oncology</i> , 1993 , 5, 900-7	4.2	22
109	Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. <i>American Journal of Clinical Pathology</i> , 1993 , 99, 736-40	1.9	16
108	Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. <i>BMJ: British Medical Journal</i> , 1993 , 306, 1684-5		3
107	High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. <i>Journal of Clinical Oncology</i> , 1993 , 11, 1132-43	2.2	428
106	Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. <i>Cancer</i> , 1993 , 71, 3942-6	6.4	71
105	Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. <i>International Journal of Cancer</i> , 1993 , 53, 401-8	7.5	52
104	Cell growth regulation in epithelial ovarian cancer. <i>Cancer</i> , 1993 , 71, 1597-601	6.4	66
103	Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1993 , 100, 1120-4	3.7	36
102	Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. <i>Journal of Clinical Investigation</i> , 1993 , 92, 2440-7	15.9	10
101	p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. <i>Journal of Histochemistry and Cytochemistry</i> , 1992 , 40, 1047-51	3.4	92
100	The use of tumor markers in the management of patients with gynecologic carcinomas. <i>Clinical Obstetrics and Gynecology</i> , 1992 , 35, 45-54	1.7	8
99	Biology and therapy with biologic agents in gynecologic cancer. <i>Current Opinion in Oncology</i> , 1992 , 4, 946-54	4.2	3
98	The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. <i>American Journal of Obstetrics and Gynecology</i> , 1992 , 167, 1877-82	6.4	6
97	Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. <i>American Journal of Obstetrics and Gynecology</i> , 1992 , 166, 997-1007	6.4	91
96	Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. <i>American Journal of Obstetrics and Gynecology</i> , 1992 , 166, 676-84	6.4	85
95	Ploidy analysis of epithelial ovarian cancers using image cytometry. <i>Gynecologic Oncology</i> , 1992 , 44, 61-54.9		22
94	Ha-ras polymorphisms in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1992 , 45, 299-302	4.9	1

93	Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. <i>Journal of Clinical Oncology</i> , 1992 , 10, 1057-65	2.2	13
92	Oncogenes in Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992 , 6, 813-827	3.1	16
91	A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. <i>International Journal of Cancer</i> , 1992 , 51, 772-9	7.5	17
90	Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. <i>Cancer</i> , 1992 , 69, 2894-904	6.4	4
89	Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. <i>Cancer</i> , 1992 , 70, 1115-23	6.4	2
88	Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. <i>Cancer</i> , 1992 , 70, 2137-42	6.4	7
87	Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. <i>International Journal of Cancer</i> , 1991 , 49, 704-10	7.5	20
86	Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. <i>Cancer</i> , 1991 , 68, 1272-8	6.4	19
85	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 164, 745-50	6.4	100
84	Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 165, 640-6	6.4	58
83	Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 164, 15-21	6.4	229
82	Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 165, 1356-62	6.4	62
81	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 164, 669-74	6.4	182
80	4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. <i>Journal of Clinical Oncology</i> , 1991 , 9, 85-93	2.2	72
79	The role of tumor markers in gynecologic oncology. <i>Obstetrical and Gynecological Survey</i> , 1990 , 45, 570-72.4		21
78	Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. <i>American Journal of Clinical Pathology</i> , 1990 , 94, 8-13	1.9	31
77	Gynecologic tumor markers. <i>Journal of Surgical Oncology</i> , 1990 , 6, 305-13		14
76	The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. <i>Cancer</i> , 1990 , 66, 431-6	6.4	48

75	Reactivity of Polyclonal and Two Monoclonal Antibodies with Cell Subsets Isolated from Cystic Fluids of Ovarian Serous Neoplasms. <i>Tumori</i> , 1990 , 76, 505-510	1.7	2
74	The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. <i>American Journal of Obstetrics and Gynecology</i> , 1990 , 163, 1164-7	6.4	41
73	Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 1990 , 163, 1204-9	6.4	42
72	Heterogeneity of antigen expression in advanced epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1990 , 162, 883-8	6.4	25
71	Antigenic heterogeneity in human ovarian cancer. <i>Gynecologic Oncology</i> , 1990 , 38, 12-6	4.9	13
70	High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1990 , 38, 386-91	4.9	43
69	Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. <i>Gynecologic Oncology</i> , 1990 , 36, 299-305	4.9	80
68	CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. <i>Gynecologic Oncology</i> , 1990 , 36, 161-5	4.9	27
67	Autologous bone marrow transplantation for acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1989 , 7, 1594-601	2.2	55
66	Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. <i>International Journal of Cancer</i> , 1989 , 43, 55-60	7.5	24
65	High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. <i>Cancer Chemotherapy and Pharmacology</i> , 1989 , 23, 377-83	3.5	21
64	Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. <i>American Journal of Obstetrics and Gynecology</i> , 1989 , 161, 1258-63	6.4	14
63	Epidermal growth factor receptor expression in normal and malignant endometrium. <i>American Journal of Obstetrics and Gynecology</i> , 1989 , 161, 1247-52	6.4	72
62	CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. <i>American Journal of Obstetrics and Gynecology</i> , 1989 , 160, 354-5	6.4	2
61	CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. <i>Acta Oncologica</i> , 1989 , 28, 655-7	3.2	37
60	The CA 125 tumour-associated antigen: a review of the literature. <i>Human Reproduction</i> , 1989 , 4, 1-12	5.7	551
59	Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. <i>Journal of Clinical Investigation</i> , 1989 , 83, 921-6	15.9	109
58	An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. <i>Gynecologic Oncology</i> , 1988 , 30, 7-14	4.9	90

57	Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. <i>American Journal of Obstetrics and Gynecology</i> , 1988 , 159, 341-6	6.4	172
56	Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. <i>New England Journal of Medicine</i> , 1988 , 318, 869-76	59.2	616
55	Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. <i>Transplantation</i> , 1988 , 46, 57-60	1.8	35
54	High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 1988 , 6, 1368-76	2.2	306
53	The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. <i>Biochemical and Biophysical Research Communications</i> , 1987 , 149, 969-74	3.4	22
52	Pros and cons of gynecologic tumor markers. <i>Cancer</i> , 1987 , 60, 1984-92	6.4	32
51	Co-expression of human cancer-associated epitopes on mucin molecules. <i>International Journal of Cancer</i> , 1987 , 39, 68-72	7.5	46
50	Immunochemical characterization and radioimmunochemical detection of molecules shed by human ovarian cancer. <i>International Journal of Cancer</i> , 1987 , 40, 592-7	7.5	11
49	Homologous and heterologous desensitization of proto-oncogene c-fos expression in murine peritoneal macrophages. <i>Journal of Cellular Physiology</i> , 1987 , 131, 36-42	7	24
48	CA 125 serum levels correlated with second-look operations among ovarian cancer patients. <i>Obstetrics and Gynecology</i> , 1986 , 67, 685-9	4.9	104
47	Elevated serum concentrations of CA-125 in patients with advanced endometriosis. <i>Fertility and Sterility</i> , 1986 , 45, 630-4	4.8	278
46	Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. <i>Leukemia Research</i> , 1986 , 10, 35-42	2.7	9
45	The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1986 , 155, 56-60	6.4	101
44	High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. <i>Journal of Clinical Oncology</i> , 1986 , 4, 646-54	2.2	95
43	Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. <i>Annals of Surgery</i> , 1985 , 202, 440-5	7.8	16
42	Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. <i>Journal of Clinical Oncology</i> , 1985 , 3, 1355-63	2.2	41
41	Monitoring Epithelial Ovarian Cancer. <i>Laboratory Medicine</i> , 1985 , 16, 315-318	1.6	4
40	Reply to Davies et al. <i>American Journal of Obstetrics and Gynecology</i> , 1985 , 151, 420	6.4	2

39	A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 1985 , 152, 911-3	6.4	18
38	Intraperitoneal immunotherapy of epithelial ovarian carcinoma with <i>Corynebacterium parvum</i> . <i>American Journal of Obstetrics and Gynecology</i> , 1985 , 152, 1003-10	6.4	34
37	Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1985 , 151, 981-6	6.4	159
36	Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 1985 , 22, 115-20	4.9	78
35	Recent advances in the immunodiagnosis of epithelial ovarian carcinoma. <i>Cancer Treatment and Research</i> , 1985 , 23-35	3.5	2
34	Somatic activation of rasK gene in a human ovarian carcinoma. <i>Science</i> , 1984 , 223, 698-701	33.3	83
33	Clinical applications of monoclonal antibodies in acute leukemia. <i>Annals of the New York Academy of Sciences</i> , 1984 , 428, 308-17	6.5	5
32	Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. <i>American Journal of Obstetrics and Gynecology</i> , 1984 , 148, 1057-8	6.4	243
31	Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. <i>American Journal of Obstetrics and Gynecology</i> , 1984 , 149, 553-9	6.4	148
30	Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. <i>International Journal of Cancer</i> , 1983 , 32, 547-54	7.5	74
29	Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. <i>International Journal of Immunopharmacology</i> , 1983 , 5, 307-14		12
28	A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. <i>New England Journal of Medicine</i> , 1983 , 309, 883-7	59.2	1714
27	Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. <i>Clinical Immunology and Immunopathology</i> , 1983 , 28, 101-14		55
26	Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. <i>American Journal of Obstetrics and Gynecology</i> , 1983 , 146, 607-12	6.4	18
25	Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. <i>American Journal of Clinical Pathology</i> , 1983 , 79, 98-104	1.9	307
24	The Immunobiology of Ovarian Carcinoma. <i>Cancer Treatment and Research</i> , 1983 , 187-226	3.5	2
23	Reactivity of a monoclonal antibody with human ovarian carcinoma. <i>Journal of Clinical Investigation</i> , 1981 , 68, 1331-7	15.9	1168
22	Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. <i>Journal of the National Cancer Institute</i> , 1980 , 64, 365-72	9.7	8

21	New approach to serotherapy of human ovarian carcinoma. <i>Gynecologic Oncology</i> , 1980 , 10, 370	4.9	2
20	High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. <i>American Journal of Medicine</i> , 1980 , 68, 370-6	2.4	140
19	The half-life of aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human blood monocytes. <i>Chemico-Biological Interactions</i> , 1976 , 14, 379-82	5	3
18	Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. <i>Journal of the National Cancer Institute</i> , 1976 , 56, 829-32	9.7	26
17	Induction of tumor immunity by intratumoral chemotherapy. <i>Annals of the New York Academy of Sciences</i> , 1976 , 276, 565-72	6.5	17
16	Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. <i>Annals of the New York Academy of Sciences</i> , 1976 , 277, 60-93	6.5	86
15	Eradication of microscopic lymph nodes metastases after injection of living BCG adjacent to the primary tumor. <i>Journal of the National Cancer Institute</i> , 1975 , 55, 1345-52	9.7	17
14	Local antitumor activity of a primary and an anamnestic response to a syngeneic guinea pig hepatoma. <i>Journal of the National Cancer Institute</i> , 1975 , 55, 989-94	9.7	7
13	Acquired cellular immunity: extracellular killing of <i>Listeria monocytogenes</i> by a product of immunologically activated macrophages. <i>Cellular Immunology</i> , 1974 , 10, 248-59	4.4	56
12	Intracolonic injection of BCG in the rhesus monkey. <i>Journal of the National Cancer Institute</i> , 1974 , 53, 1423-6	9.7	4
11	Destruction of syngeneic tumors by tuberculin-stimulated peritoneal exudate cells from guinea pigs immunized to <i>Mycobacterium bovis</i> (strain BCG). <i>Journal of the National Cancer Institute</i> , 1974 , 53, 541-6	9.7	6
10	Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. <i>Journal of the National Cancer Institute</i> , 1974 , 53, 591-3	9.7	10
9	BCG and cancer. <i>New England Journal of Medicine</i> , 1974 , 290, 1458-69	59.2	152
8	BCG and cancer (first of two parts). <i>New England Journal of Medicine</i> , 1974 , 290, 1413-20	59.2	287
7	Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. <i>Nature</i> , 1974 , 250, 664-5	50.4	43
6	Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. <i>Journal of Experimental Medicine</i> , 1971 , 133, 202-15	16.6	28
5	Heterogeneity of the cellular immune response. I. Kinetics of lymphocyte stimulation during sensitization and recovery from tolerance. <i>Journal of Experimental Medicine</i> , 1971 , 133, 187-201	16.6	26
4	Nature of the immunogen in crystalline serum albumins. <i>Immunochemistry</i> , 1970 , 7, 118-24		11

- 3 In vitro assay of endotoxin by the inhibition of macrophage migration. *Journal of Bacteriology*, **1967**, 93, 15-20 3.5 24
- 2 Targeting therapies in cancer: opportunities in ovarian cancer 167-182
- 1 Molecular targets for epithelial ovarian cancer 606-618